Prospective, Randomised, Placebo-controlled Study of Polyvalent Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies
Latest Information Update: 11 Jul 2022
Price :
$35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Acronyms TINISS
- 07 Jul 2022 Planned End Date changed from 1 Dec 2022 to 1 Jul 2026.
- 07 Jul 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2025.
- 31 Aug 2021 Planned End Date changed from 1 Jul 2021 to 1 Dec 2022.